药物治疗向GABA-谷氨酸神经传递治疗耐药抑郁症的药物治疗方法
Courtney M Vecera1, Alan C Courtes1, Gregory Jones1
1Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, TX 77054, USA.
Pharmaceuticals (Basel, Switzerland)
|November 25, 2023
概括
针对谷氨酸和GABA系统的新型抗抑郁药在治疗耐药性抑郁症 (TRD) 中表现有前途. 凯胺和神经类固醇等研究药物为那些对传统疗法没有反应的患者提供了新的希望.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 耐治疗抑郁症 (TRD) 影响了许多患有严重抑郁症 (MDD) 的患者.
- 目前对TRD的治疗方法有限,需要新的治疗点.
- 中枢神经系统 (CNS) 神经递质L-谷氨酸和氨酸 (GABA) 的不平衡与TRD病理生理学有关.
研究的目的:
- 审查针对L-谷氨酸和GABA系统的试验性抗抑郁药物.
- 评估这些新型化合物的证据,作用机制和安全概况.
- 为TRD的治疗进展提供最新的视角.
主要方法:
- 关于新型抗抑郁药研究的综合文献综述.
- 分析临床试验数据的疗效和安全性.
- 评估作用机制,重点关注NMDA受体对抗和GABA调节.
主要成果:
- 纳米甲基D-酸盐 (NMDA) 受体对抗剂,包括胺和胺,表现出强大的反应.
- 通过NMDA-甘氨酸位调节剂 (D-cycloserine, apimostinel) 和结合的德克斯特罗米多芬-布罗 (AXS-05) 显示出有前途的结果.
- 积极的GABAA受体调节剂,如布雷克萨诺龙,正在成为潜在的治疗方法.
- 埃斯凯特胺,奥维利提和布雷克萨诺龙都是FDA批准的,用于特定的抑郁症.
结论:
- 针对L-谷氨酸和GABA神经传递的进展为TRD提供了新的治疗途径.
- 几种新型药物显示出显著的前景,其中一些已经被FDA批准.
- 进一步的研究是有必要的,考虑到一些新兴治疗的安全性.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
414
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
414
Antiepileptic Drugs: Glutamate Antagonists
376
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
376
Antidepressant Drugs: MAOIs and Other Agents
248
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
248
Psychosis: Goals of Pharmacotherapy
142
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
142
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Sedatives and Hypnotics Drugs: Miscellaneous Agents
179
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
179


